Frequently Asked Questions about the BPC-157 Everything you need to know about the reference regenerative peptide in preclinical research What is the BPC-157
A 2026 UK review of how HGF activates repair Schwann cells (Ko 2018, Scientific Reports ), the 2021 rat sciatic-nerve study where Dihexa + stem cells improved motor recovery, the VM202 / Engensis HGF gene-therapy Phase 3 in painful diabetic peripheral neuropathy (results posted Jan 2025), chemotherapy-induced neuropathy (CIPN) and the duloxetine question, and the 2026 AthiraLeonaBio pivot taking the oral HGF/MET modulator ATH-1105 into ALS with an honest account of why Dihexa still has zero human neuropathy data Read the full review Neuroscience 27 May 2026 Dihexa for Migraine & Chronic Migraine: The 2026 UK Review Rigorous 2026 UK review of Dihexa for migraine and chronic migraine
Current access is limited to clinical trials and research peptide suppliers
Every intervention has tradeoffs, and you deserve to know exactly what they are
We work with FDA-registered, U.S.-based compounding pharmacies that comply with USP 797 and 795 standards
We also work with Freedom Diagnostics , an independent third-party testing facility, to support our quality assurance efforts